In today’s episode, we had the pleasure of speaking with Vishal A. Patel, MD, FAAD, FACMS, about the FDA approval of adjuvant cemiplimab-rwlc (Libtayo) for the treatment of patients with high-risk cutaneous squamous cell carcinoma (CSCC). Dr Patel is an associate professor of dermatology at the GW School of Medicine & Health Sciences, as well as the director of the Cutaneous Oncology Program at the GW Cancer Center in Washington, DC.

In our exclusive interview, Dr Patel discussed the clinical relevance of this approval, key details about the pivotal phase 3 C-POST trial (NCT03969004), and the safety profile of cemiplimab in patients with CSCC.